PURPOSE: This randomized multicenter study was designed to compare the activity of a high-dose doxorubicin-containing chemotherapy regimen with a conventional standard-dose regimen in adult patients with advanced soft tissue sarcomas (ASTS). PATIENTS AND METHODS: Between 1992 and 1995, 314 patients were randomized to receive a standard-dose regimen (arm A), containing doxorubicin (50 mg/m(2) on day 1) and ifosfamide (5 g/m(2) on day 1), or an intensified regimen (arm B), combining doxorubicin (75 mg/m(2) on day 1), the same ifosfamide dose, and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; sargramostim, 250 microgram/m(2) on days 3 to 16); all courses were repeated every 3 weeks. RESULTS: The median age of the 294 eligible patients was 50 years. They received a median of five chemotherapy cycles. The median dose and relative doxorubicin dose-intensity achieved were 245 mg and 97% in arm A and 360 mg and 99% in arm B, respectively. Thirty-eight percent and 23% of ...
Import Data And Price Of ifosfamide , www.eximpulse.com Eximpulse Services will provide you the latest and relevant market intelligence reports of ifosfamide Import Data. You can find live data of maximum number of ports of India which is based on updated shipment data of Indian Customs. Only previous two days data will be seen on website. You can use this ifosfamide import data for multiple kinds of analysis; lets say Import price, Quantity, market scenarios, Price trends, Duty optimization and many more. You can go through some of the sample shipment records for ifosfamide import data mentioned above. Here on Eximpulse Services you will get all kind of free sample as well as detailed reports of Export/ Import data as per your requirement. To get in touch for any kind of enquiry related to free sample or detailed report contact on +91-120-408-4957, +91-120-408-4958,+91-120-428-4019.. Data post 2012 as per Notification No.18/2012 - Customs(N.T.) and does not have names of Indian companies and ...
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide alone is more effective than ifosfamide plus paclitaxel in treating patients with cancer of the uterus.. PURPOSE: Randomized phase III trial to compare the effectiveness of ifosfamide with or without paclitaxel in treating patients with advanced, refractory, or recurrent cancer of the uterus. ...
This trial is a multicentric study aiming to assess the evolution of the serum ifosfamide concentrations and its serum metabolites in patients treated for an Soft Tissue Sarcoma and co-exposed to Aprepitant.. The study will be conducted on a population of patients treated with Doxorubicin and Ifosfamide. The Aprepitant can be prescribed to patients from cycle 2, according to the current recommendations. Doxorubicin, Ifosfamide and Aprepitant will be administered in the context of routine care. The follow-up during the treatment period and the clinical, biological and radiological assessments will be performed according to the standard of each centre.. Patients will be followed during the two first cycles of treatment. For the pharmacokinetic study, blood samples will be collected at different time points during the 2 treatment cycles. ...
The chemotherapy drug ifosfamide is used in the treatment of several childhood cancers. While effective, its use in children results in a 30% incidence of nephrotoxicity, and 5% incidence of Fanconi syndrome. This late effect is caused by oxidative damage, generated by chloroacetaldehyde, a toxic metabolite of ifosfamide cytochrome P450-mediated bioactivation in the kidney tubules. N-acetylcysteine has been identified as a promising strategy to mitigate nephrotoxicity through its antioxidant and glutathione stimulating properties. Furthermore, with current use in children for acetaminophen poisoning, its clinical utility is evident. Both cell and animal models have demonstrated n-acetylcysteines effectiveness in mitigating ifosfamide kidney toxicity. However, there is no data available to suggest the safe use of n-acetylcysteine with respect to maintenance of ifosfamides chemotherapeutic integrity. There is also a lack of information suggesting that the current dose for acetaminophen overdose will be
Ifosfamide for Injection vials contain ifosfamide sterile powder. Reconstituted solutions should be used within 24 hours if stored at room temperature, or within 72 hours if refrigerated. Use further diluted solutions immediately. Injections of ifosfamide into veins of the rat tail, the rabbit ear and the dog forepaw were well tolerated.
To determine the efficacy of the addition of ifosfamide to cisplatin plus etoposide (VIP), or vinblastine (VeIP), in patients with recurrent germ cell tumors. DESIGN: Nonrandomized, prospective phase II trial. SETTING: Tertiary referral university hospital. PATIENTS: Fifty-six of fifty-eight entered patients with measurable and progressive recurrent germ cell tumors of testicular (46 patients), ovarian (1 patient), and extragonadal (9 patients) origin were evaluable for response after not being cured with cisplatin, vinblastine, and etoposide regimens. INTERVENTIONS: Patients were administered cisplatin (20 mg/m2 body surface area daily for 5 days), ifosfamide (1.2 g daily for 5 days), plus either etoposide (75 mg daily for 5 days) or vinblastine (0.11 mg/kg body weight on days 1 and 2). In addition, vigorous intravenous hydration therapy with normal saline (100 to 125 mL/h) was administered during the treatment course. Uroepithelial protective agents, N-acetylcysteine (orally) or mesna ...
West-Wards Ifosfamide Injection is indicated for use in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. It should be used in combination with mesna for prophylaxis of hemorrhagic cystitis.. According to IMS Health, US sales of Ifosfamide Injection, 1g/20mL vials, were approximately $0.6 million in the 12 months ending October 2017.. Important safety information. Warning: MYELOSUPPRESSION, NEUROTOXICITY AND UROTOXICITY. Myelosuppression can be severe and lead to fatal infections. Monitor blood counts prior to and at intervals after each treatment cycle. CNS toxicities can be severe and result in encephalopathy and death. Monitor for CNS toxicity and discontinue treatment for encephalopathy. Nephrotoxicity can be severe and result in renal failure. Hemorrhagic cystitis can be severe and can be reduced by the prophylactic use of mesna.. Warnings and Precautions. The following warnings and precautions should be taken when ...
The oxazaphosphorines cyclophosphamide, ifosfamide and trofosfamide remain a clinically useful class of anticancer drugs with substantial antitumour activity against a variety of solid tumors and hematological malignancies. A major limitation to their use is tumour resistance, which is due to multiple mechanisms that include increased DNA repair, increased cellular thiol levels, glutathione S-transferase and aldehyde dehydrogenase activities, and altered cell-death response to DNA damage. These mechanisms have been recently re-examined with the aid of sensitive analytical techniques, high-throughput proteomic and genomic approaches, and powerful pharmacogenetic tools. Oxazaphosphorine resistance, together with dose-limiting toxicity (mainly neutropenia and neurotoxicity), significantly hinders chemotherapy in patients, and hence, there is compelling need to find ways to overcome it. Four major approaches are currently being explored in preclinical models, some also in patients: combination with ...
Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract Academic Article ...
The goal of this clinical research study is to learn if the combination of the drugs ifosfamide, carboplatin, and etoposide (a routine chemotherapy called ICE) and panobinostat can help to control relapsed or refractory Hodgkins lymphoma. The safety of this drug combination will also be studied.
Ifosfamide merupakan golongan alkilator dan agen antineoplastik. Berbagai jenis kanker antara lain limfoma hodgkin dan limfoma non hodgkin, kanker vesika urinaria, sarkoma, kanker kepala-leher, tumor solid
Ifosfamide- ന്റെ ഉപയോഗങ്ങൾ, ഡോസേജ്, പാർശ്വഫലങ്ങൾ, പ്രയോജനങ്ങൾ, പ്രതിപ്രവർത്തനങ്ങൾ, മുന്നറിയിപ്പ് എന്നിവ കണ്ടെത്തുക
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors ...
17-DMAG HCl (Alvespimycin) chondroblastic (36%) and the most frequent major tumor sites had been the 17-DMAG HCl (Alvespimycin) femur (64%) tibia (21%) humerus (7%) and pelvis (7%). All individuals had been treated with high-dose methotrexate doxorubicin and cisplatin with one affected person receiving extra ifosfamide and two individuals receiving extra ifosfamide and etoposide. Extra patient characteristics is seen in Extra file 2: Desk S1. GD2 manifestation The amount of variability between three 3rd party observers was evaluated to be nonsignificant utilizing a two-factor ANOVA without alternative (p?=?0.24) as well as the intraclass relationship coefficient was found to become 0.72 suggesting a good to good Rabbit polyclonal to SHP-2.SHP-2 a SH2-containing a ubiquitously expressed tyrosine-specific protein phosphatase.It participates in signaling events downstream of receptors for growth factors, cytokines, hormones, antigens and extracellular matrices in the control of cell growth,. degree ...
ChemoGLO - is a useful tool to monitor your environmental exposure to five common antineoplastic agents 5-fluorouracil, ifosfamide, cyclophosphamide, docetaxel, methotrexate, platinum analogues, paclitaxel, Busulfan, Etoposide, Cytarabine, Doxorubicin, Daunorubicin, Vincristine with HDClean product.
ChemoGLO - is a useful tool to monitor your environmental exposure to five common antineoplastic agents 5-fluorouracil, ifosfamide, cyclophosphamide, docetaxel, methotrexate, platinum analogues, paclitaxel, Busulfan, Etoposide, Cytarabine, Doxorubicin, Daunorubicin, Vincristine with HDClean product.
Now Im back in the hospital for a few days, getting the VAC (Vincristine/Adriamycin/Cyclophosphamide). For some reason, every time I come in as an in-patient, it takes FOREVER to get the chemo actually started. Today we got to the patient ward around 11 and they didnt start the chemo until almost 4pm. I guess they need to wait for the orders to come through and the pharmacy to mix the drugs and such. Still, its kind of annoying that I come in here and have to sit around for hours. The nurse just hung my Adriamycin bag (around 5pm), so now Ive got 48 hours to wait til I get out of here. Luckily, after five of these VAC cycles, Ill stop getting Adriamycin and this set of drugs will only take one day. The other set (IE - Ifosfamide/Etoposide) will still take 4 days, but I may move to out-patient for that one eventually. The out-patient schedule is fairly grueling, though - you basically have to come in at 7am every day for 12 hours. Still, I suspect it might be better than staying in the ...
For those of you following at home, this round is ye olde etoposide and ifosfamide, which cause the usual nausea, low blood counts, fatigue, etc. Since my counts were low last week, theyre only giving me 80% of the normal dose for this drug, which means ostensibly only 4 days instead of 5 in the hospital. Unfortunately, we got started late on Monday around 5pm, so Ill end up being here til Fri morning anyhow. Not a huge deal, since I have to be here for radiation at noon anyway, but it would have been nice to have a little less time in F-ground ...
TY - JOUR. T1 - Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. AU - Magnan, Heather. AU - Goodbody, Christine M.. AU - Riedel, Elyn. AU - Pratilas, Christine A.. AU - Wexler, Leonard H.. AU - Chou, Alexander J.. PY - 2015/4/1. Y1 - 2015/4/1. N2 - Background: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. Procedure: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800mg/m2/day × 5 days per cycle to 2,800mg/m2/day × 5 days per cycle. Results: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) ...
Of 224 patients entered on this study, 30 were ineligible for a variety of reasons, leaving 194 evaluable patients. Early in the study, the dose of the combination regimen was reduced by 20% (1 day) because of toxicity. The investigational arms were balanced for age, grade, and Gynecologic Oncology Group performance status. Percentages of adverse effects reported in 191 patients receiving chemotherapy included (ifosfamide/cisplatin-ifosfamide) grade 3 or 4 granulocytopenia (36/60), grade 3 or 4 anemia (8/17), grade 3 or 4 central nervous system toxicity (19/14), and grade 3 or 4 peripheral neuropathy (1/12). Treatment may have contributed to the deaths of 6 patients treated with full doses of ifosfamide and cisplatin for 5 days. The proportion of patients responding to ifosfamide alone versus ifosfamide-cisplatin therapy was (0.36 versus 0.54) overall, 0.47 versus 0.61 for pelvic, 0.21 versus 0.54 for lung, and 0.33 versus 0.40 for other metastatic sites of measurable disease. The relative ...
Learn about the potential side effects of ifosfamide/mesna. Includes common and rare side effects information for consumers and healthcare professionals.
AMBICA PHARMA - Manufacturer,Supplier,Exporter of ifosfamide with mesna from India. We offer best quality of products at a best price rate.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice. ...
Amifostine protects normal tissue from the cytotoxic damage induced by radiation and chemotherapy. in this study. 39 consecutive newly diagnosed children with osteosarcoma were assessed; 20 received amifostine and 19 did not. the chemotherapy regimen included an induction phase of three cycles of cisplatin (100 mg/m(2)), carboplatin (500 mg/m(2)), and doxorubicin (60 mg/m(2)), followed by surgery. Alternating cycles of cisplatin/ifosfamide (9 mg/m(2)), ifosfamide/doxorubicin. carboplatin/doxorubicin, and ifosfamide/carboplatin were administered every 3 weeks to complete 26 weeks of treatment. Amifostine was administered 15 minutes before the infusions of cisplatin and carboplatin in a total of 193 infusions. Side effects during infusions and renal, hearing, and bone marrow toxicities were evaluated and compared between the two groups. Hypotension was observed in 28 (14.5%) infusions. No patient required discontinuation of therapy. Fewer than two episodes of vomiting occurred in 130 (71%) ...
For localized sarcomas, surgery and radiation are standard of care, resulting in cure rates of about 50%. Of the remaining patients, about 60% have metastatic disease. Despite surgery, radiation, and chemotherapy, overall survival for patients with metastatic sarcoma treated with first-line doxorubicin plus ifosfamide is about 12 months. A variety of chemotherapies have been studied.. One debate concerns how best to deploy doxorubicin and ifosfamide-in combination or as single-agent therapy. The ongoing EORTC 62012 study, completed in 2010, should answer that question. The study is comparing doxorubicin vs the combination of full-dose doxorubicin plus full-dose ifosfamide as first-line therapy for soft-tissue sarcoma in about 400 patients.. Dr. Blay emphasized that disease stabilization is probably a more important endpoint than response rates in clinical trials. "About 5% of all patients with soft-tissue sarcomas will be long-term survivors, with no progression at 5 years. These patients ...
There were no toxic deaths in either the infusional or fractionated ICE studies. The toxicities in the infusional studyr are not fully described but the same group also published a study of ICE salvage in 163 patients with non-Hodgkin lymphoma.r In this group, thrombocytopenia was the dose limiting toxicity with grade 3/4 thrombocytopenia occurring in 29% of cycles given and 30% of patients requiring platelet transfusion. 13% of cycles were complicated by grade 4 neutropenia requiring hospital admission. The neutrophil nadir occurred 7 to 9 days after the beginning of the cycle. Anaemia was a common occurrence with 98 patients requiring red cell transfusions. Non-haematological toxicities were uncommon and included gross haematuria in 4 of 381 cycles, one case of reversible nephrotoxicity, two cardiac toxicities (congestive cardiac failure & supraventricular tachycardia) and 5 cases of neurological toxicity (1 peripheral neuropathy and 4 confusion due to ifosfamide-induced encephalopathy). The ...
RFC 5703 Sieve MIME Operations October 2009 When used in the context of a "foreverypart" iterator, the MIME part to be replaced is the "current" MIME part. If the current MIME context is a multipart MIME part, the entire multipart MIME part is replaced, which would alter the MIME structure of the message by eliminating all of the children of the multipart part. (Replacing a non-multipart MIME part within a "foreverypart" loop context does not alter the overall message structure.) If the MIME structure is altered, the change takes effect immediately: the "foreverypart" iterator that is executing does not go into the no-longer existing body parts, and subsequent "foreverypart" iterators would use the new message structure. When used outside the context of a "foreverypart" loop, the MIME part to be replaced is the entire message. If the ":mime" parameter is not specified, the replacement string is a text/plain part in UTF-8 [RFC3629]. If the ":mime" parameter is specified, then the replacement ...
For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is called neoadjuvant therapy and has not previously been demonstrated to improve outcomes in soft tissue sarcoma (STS). Soft tissue […]. ...
For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival.... Continue Reading ...
EORTC STBSG. Ongoing clinical trials Venice, November 4th. A RANDOMIZED STUDY COMPARING NEOADJUVANT CHEMOTHERAPY ETOPOSIDE + IFOSFAMIDE + ADRIAMYCIN (EIA) COMBINED WITH REGIONAL HYPERTHERMIA (RHT) VS. NEOADJUVANT CHEMOTHERAPY ALONE Slideshow 6012314 by sydney-ayers
There are a couple reasons why this is important for me right now. The first reason is that all three of the drugs that Im receiving during my current chemotherapy regimen, Ifosfamide, Carboplatin, and Etoposide, share a common side effect: low white blood cell count with increased risk of infection.. Neutrophils are one type of white blood cells. They usually make up between fifty and seventy percent of a persons circulating white blood cells. They serve as the primary defense against infections by destroying bacteria in the blood. When the number of neutrophils in a persons bloodstream drops below a certain level, that person is said to be suffering from neutropenia.. If a persons neutrophil count falls below certain levels, even the bacteria normally present in our bodies could cause potentially life-threatening infections. Lowered counts can also result in a delay of scheduled chemotherapy. If counts arent above certain levels, its too dangerous to proceed until they bounce back. ...
Doctors give unbiased, helpful information on indications, contra-indications, benefits, and complications: Dr. Romero on chemo bandanas: Choosing chemo depends on many factors, so only your doctor can decide what might work for you. Drugs you havent mentioned include altretamine, capecitabine, cytoxan, (cyclophosphamide) vinorelbine, ifosfamide, etoposide, and irinotecan. There are also several hormonal agents. And a clinical trial might be an option. Check out www.Cancer.Gov for more info. And good luck.
VIP regimen 2: chemotherapy protocol consisting of vincristine, ifosfamide and peplomycin for treatment of newly diagnosed stage D2 prostate cancer
This trial is comparing the efficacy and tolerability of two dose levels of MEDI 551 versus rituximab, when used in combination with salvage ifosfamide +
As a follow-up to vulnerability reported in MFSA 2008-12 Mozilla has checked similar constructs in the rest of the MIME handling code. Although no further buffer overflows were found we changed several function calls to use safer versions of the string routines that will be more robust in the face of future code changes. ...
uft8: 仑单実斏竟丫柧扻您愢具趟皈丶颚 Of course, I cant read any Chinese, so I have no idea if those are the right characters or just gibberish ...
S-nail is a mail processing system with a command syntax reminiscent of ed with lines replaced by messages. It is based on Heirloom mailx that is based upon Berkeley Mail 8.1, is intended to provide the functionality of the POSIX mailx command and offers (mostly optional) extensions for IDNA, MIME, S/MIME, SMTP, POP3 and IMAP. It is usable as a mail batch language. ...
S-nail is a mail processing system with a command syntax reminiscent of ed, with lines replaced by messages. It is based on Heirloom mailx, which in turn is based upon Berkeley Mail 8.1. It is intended to provide the functionality of the POSIX mailx command and offers (mostly optional) extensions for IDNA, MIME, S/MIME, SMTP, POP3 and IMAP. It is usable as a mail batch language. ...
The oxazaphosphorines including cyclophosphamide (CPA), ifosfamide (IFO), and trofosfamide represent an important group of therapeutic agents due to their substantial antitumor and immuno-modulating activity. CPA is widely used as an anticancer drug, an immunosuppressant, and for the mobilization of hematopoetic progenitor cells from the bone marrow into peripheral blood prior to bone marrow transplantation for aplastic anemia, leukemia, and other malignancies. New oxazaphosphorines derivatives have been developed in an attempt to improve selectivity and response with reduced toxicity. These derivatives include mafosfamide (NSC 345842), glufosfamide (D19575, β-D-glucosylisophosphoramide mustard), NSC 612567 (aldophosphamide perhydrothiazine), and NSC 613060 (aldophosphamide thiazolidine). This review highlights the metabolism and transport of these oxazaphosphorines (mainly CPA and IFO, as these two oxazaphosphorine drugs are the most widely used alkylating agents) and the clinical ...
9. Bokemeyer C, Franzke A, Hartman JT, et al: A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin 25. Dupuis-Girod S, Hartman O, Benhamou E, et al: Will high dose with peripheral blood stem cell support for the treatment of patients chemotherapy followed by autologous bone marrow transplantation with advanced soft tissue sarcomas. Cancer 80:1221-1227, 1997 supplant cranio-spinal irradiation in young children treated for medul- 10. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, 26. Mason WP, Grovas A, Halpern S, et al: Intensive chemotherapy autologous bone marrow transplantation, and 13-cis-retinoic acid: and bone marrow rescue for young children with newly diagnosed Childrens Cancer Group. N Engl J Med 341:1165-1173, 1999 malignant brain tumors. J Clin Oncol 16:210-221, 1998 11. Grupp SA, Stern JW, Bunin N, et al: Tandem high-dose therapy 27. Gajjar A, Kuhl J, Epelman S, et al: ...
Authors: HM Prince, MJ Millward, D Rischin, D Blakey, P Francis, P Gates, P Chapple, M Quinn, S Juneja, M Wolf, EH Januszewicz, JF Seymour, M Brettell, A Strickland, J Zalcberg, G Richardson, J Scarlett, P Briggs, GC Toner
Cancer Transl Med, Official publication of Chinese Translational Medicine and Biology Technology Innovation Alliance, and Cipher Ground
This medicine may cause a brain disease called encephalopathy. Tell your doctor right away if you have the following symptoms while taking this medicine: agitation, back pain, blurred vision, coma, confusion, dizziness, drowsiness, fever, hallucinations, headache, irritability, mood or mental changes, seizures, stiff neck, or unusual tiredness or weakness. This medicine may cause drowsiness, trouble in thinking, trouble in controlling movements, or trouble in seeing clearly. Make sure you know how you react to this medicine before you drive, use machines, or do other jobs that require you to be alert, well-coordinated, or able to think or see well. This medicine will add to the effects of alcohol and other CNS depressants (medicines that make you drowsy or less alert). Some examples of CNS depressants are antihistamines or medicine for hay fever, other allergies, or colds; sedatives, tranquilizers, or sleeping medicine; prescription pain medicine or narcotics; medicine for seizures or ...
The Food and Drug Administration (FDA) has granted accelerated approval to olaratumab (Lartruvo®) for the treatment of some patients with soft tissue sarcoma. ...
/PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the...
The typical protocol for Ewings Sarcoma is called VAI. This stands for the 3 different chemotherapy drugs that are used: Vincristine, Doxorubicin(also known as Adriamycin) and Ifosfamide (also known as Ifex). The Vincristine is only given on Day 1 and only takes about 15-30 minutes to run. Vincristine is light sensitive and has no color. The Adriamycin runs constantly for 3 days straight. Adriamycin is light sensitive also, and is red in color. This medicine causes urine to become orange and can have long term effects on the heart. There is a lifetime max that a patient can receive of this drug because of the heart damage it can cause. Adriamycin can also burn the skin. Ifex is given once a day for 4 days. It runs for 2-3 hours each time. Ifex is not light sensitive and is colorless. This is the most potent drug that Brent is receiving. A medication called Mesna is given in addition to these drugs but is not a chemotherapy drug. Mesna is used to protect the bladder and kidneys from the effects ...
The typical protocol for Ewings Sarcoma is called VAI. This stands for the 3 different chemotherapy drugs that are used: Vincristine, Doxorubicin(also known as Adriamycin) and Ifosfamide (also known as Ifex). The Vincristine is only given on Day 1 and only takes about 15-30 minutes to run. Vincristine is light sensitive and has no color. The Adriamycin runs constantly for 3 days straight. Adriamycin is light sensitive also, and is red in color. This medicine causes urine to become orange and can have long term effects on the heart. There is a lifetime max that a patient can receive of this drug because of the heart damage it can cause. Adriamycin can also burn the skin. Ifex is given once a day for 4 days. It runs for 2-3 hours each time. Ifex is not light sensitive and is colorless. This is the most potent drug that Brent is receiving. A medication called Mesna is given in addition to these drugs but is not a chemotherapy drug. Mesna is used to protect the bladder and kidneys from the effects ...
We analyzed 301 patients recruited from January 1986 to July 1991 (60% male; median age 15 years). Tumors of volume ,100 mL and/or at central-axis sites qualified patients for high risk (HR, n = 241), and small extremity lesions for standard risk (SR, n = 52). Standard-risk patients received 12 courses of vincristine, cyclophosphamide, and doxorubicin alternating with actinomycin D (VACA); HR patients received ifosfamide instead of cyclophosphamide (VAIA). Tumor sites were pelvis (27%), other central axis (28%), femur (19%), or other extremity (26%). The initial tumor volume was ,100 mL in 33% of cases and , or =100 mL in 67%. Local therapy was surgery (23%), surgery plus radiotherapy (49%), or radiotherapy alone (28%). Event-free survival rates were estimated by Kaplan-Meier analyses, comparisons were done by log-rank test, and risk factors were analyzed by Cox models. Results: ...
Children with neuroblastoma undergo several cycles of intensive chemotherapy to stop disease progression with the final aim to eliminate the tumour. Chemotherapy includes carboplatin or cisplatin in various combinations with drugs such as cyclophosphamide, ifosfamide, doxorubicin, etoposide, topotecan and vincristine (1). Nevertheless, in average 1 in 5 children with stage 4 disease do not respond to therapy. Up to 50% of children that do respond experience disease recurrence with tumour resistant to multiple drugs and more aggressive behaviour that all too frequently results in death.. The development of drug resistance is the major obstacle in treatment of neuroblastoma. To tackle this problem, researchers need to study different models of disease using cell lines, 3D tumour cell models, mice models and have access to clinical samples.. The first stage in testing drugs is to understand their killing ability of cancer cells. At this stage, researchers test drugs using cell lines. Cell lines are ...